These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4074636)

  • 1. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.
    Robinson BA; Clutterbuck RD; Millar JL; McElwain TJ
    Br J Cancer; 1985 Dec; 52(6):813-22. PubMed ID: 4074636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.
    Robinson BA; Clutterbuck RD; Millar JL; McElwain TJ
    Br J Cancer; 1986 May; 53(5):607-14. PubMed ID: 3718818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.
    Dufour M; Panasci LC; St Germain J; Boulet L
    Cancer Chemother Pharmacol; 1985; 15(2):125-31. PubMed ID: 4017161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing the chemosensitization of melphalan by misonidazole.
    Randhawa VS; Stewart FA; Denekamp J; Stratford MR
    Br J Cancer; 1985 Feb; 51(2):219-28. PubMed ID: 3966979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW; Beyers KL
    Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
    Yalowich JC; Zucali JR; Gross M; Ross WE
    Cancer Res; 1985 Oct; 45(10):4921-4. PubMed ID: 3861238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays.
    Lazarus P; Dufour M; Isabel G; Panasci LC
    Cancer Chemother Pharmacol; 1986; 16(2):148-52. PubMed ID: 3948300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hyperthermia and verapamil on melphalan cytotoxicity and transport in multidrug-resistant Chinese hamster ovary cells.
    Averill-Bates DA; Courtemanche B
    Radiat Res; 1995 Jul; 143(1):17-25. PubMed ID: 7597140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marrow precursor cells (CFU-C) and murine L1210 leukemia cells.
    Vistica DT; Rabon A; Rabinovitz M
    Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):171-83. PubMed ID: 441510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.
    Selby PJ; Millar JL; Phelps TA; Gordon MY; Wilkinson R; McElwain TJ
    Cancer Chemother Pharmacol; 1981; 6(2):169-73. PubMed ID: 7307234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
    Teicher BA; Crawford JM; Holden SA; Cathcart KN
    Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
    Teicher BA; Herman TS; Hopkins RE; Menon K
    J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.
    Smith MA; Merry S; Smith JG; Kaye SB
    Br J Cancer; 1988 Jun; 57(6):576-8. PubMed ID: 3408645
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
    Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
    Chao NJ; Aihara M; Blume KG; Sikic BI
    Exp Hematol; 1990 Dec; 18(11):1193-8. PubMed ID: 2226679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A radiometric method for determining the effect of xenobiotics on murine bone marrow cell proliferation].
    Azizov RG; Merkulova TI; Rogozhina AT; Burov IuV
    Biull Eksp Biol Med; 1995 Aug; 120(8):222-4. PubMed ID: 7579293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.